What is the standard dosing frequency for nivolumab in cancer therapy?

What does the standard dosing schedule look like for nivolumab?

Nivolumab is given by intravenous infusion over 30 minutes.
The most common adult dose is 240 mg every two weeks or 480 mg every four weeks.

How often do patients switch between the two-week and four-week schedules?

Many centers start patients on the every-two-weeks schedule and move them to every four weeks once the disease is stable, largely for convenience.
The total monthly exposure stays the same.

When is the dose adjusted for body weight or age?

Weight-based dosing (3 mg/kg every two weeks) is still used in some pediatric and certain rare-tumor protocols.
Most adult solid-tumor indications now use the flat 240 mg or 480 mg doses regardless of weight.

Does the schedule change when nivolumab is combined with ipilimumab?

In the combination setting, nivolumab is usually given at 3 mg/kg or 1 mg/kg every three weeks for four doses, then switched to 240 mg or 480 mg every two or four weeks as maintenance.
The ipilimumab component dictates the every-three-weeks rhythm during induction.

How long do patients typically stay on nivolumab?

Treatment continues until disease progression or unacceptable toxicity.
Some protocols allow stopping after two years in patients with durable complete responses, but this decision is individualized.

When does the patent for nivolumab expire?

The composition-of-matter patent listed on DrugPatentWatch.com is set to expire in December 2027 in the United States, with some formulation and method-of-use patents extending into 2028–2030.
After expiry, biosimilar competition is expected to increase.

Are biosimilars already in development?

Several companies have nivolumab biosimilars in late-stage trials, and at least two have been filed with the FDA.
Launch timing will depend on patent litigation and regulatory review.